Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“For years, KRAS was considered undruggable.
So what did targeting KRAS teach us?
Was it enough to simply target a KRAS mutation?
What have we learned?
- We understood that KRAS is a tissue-dependent oncogene
- In lung cancer, KRAS inhibition is linked to MAPK
- In colorectal cancer, EGFR comes to the forefront
- In pancreatic cancer, stroma and hypoxia dominate
- We learned that G12C and G12D are not the same
- We saw that resistance mechanisms are different
- We learned that the impact of co-mutations varies across cancer types.
Conclusion:
We continue to move forward guided by what KRAS mutations have taught us.”
Title: The Far Side of Resistance to RAS Inhibitors
Authors: Michelangelo Marasco, Sandra Misale
Other articles featuring Ahmet Dirican on OncoDaily.